|
|
Bredgade 34, 1260 Copenhagen K
, Denmark
phone:+ 45 7020 2728
fax:+ 45 7020 2729
|
|
| Symbol |
Genmab |
| Exchange |
Nasdaq |
| Founded |
0 |
| Employees |
|
|
|
| www.genmab.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Antibody products for life-threatening diseases |
|
| Management |
| Lisa N. Drakeman, Ph.D., President & Chief Executive Officer; Prof. Jan G. J. van de Winkel, Ph.D., President, Research & Development & Chief Scientific Officer; David A. Eatwell, Senior Vice President & Chief Financial Officer; Annarie Lyles, Ph.D., Senior Vice President, Head of Business Development; Ole Baadsgaard, M.D. Dr.MSci., Senior Vice President, Medical Affairs |
| |
|
|
|
|
|
|
|
| Keywords |
| IgG4 antibody, therapeutics, stabilized, herapeutic, transgenic mouse |
|
|
|
| Description |
|
Genmab is dedicated to creating and developing human antibodies to help people suffering from life-threatening and debilitating diseases. Genmab's strategy is to maintain a broad pipeline of human antibody products to balance the risk inherent in drug development and maximize our chances for success. To achieve this goal, they have selected disease targets that they believe have a strong scientific and business rationale. They diversify their potential revenue stream by creating products for an array of both validated and novel targets. They also attempt to balance risk through their partnering efforts by licensing some programs at an early stage and others later to create a potentially diversified risk and revenue profile. Using the HuMAb-Mouse transgenic mouse technology licensed from Medarex, Genmab can rapidly create fully human high affinity antibodies which may have less potential to elicit allergic responses or other side effects than previous generations of antibody products which have typically contained mouse or other animal proteins. In addition, Genmab has developed UniBody, a proprietary technology which is used to create a smaller antibody format which may offer several advantages over traditional full size monoclonal antibodies. |
|
| Products / Services |
Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products.
|
|
| Technology / Differentiation |
| Genmab has recently developed UniBody, a new proprietary antibody technology that creates a stable, smaller antibody format with an anticipated longer therapeutic window than current small antibody formats. Genmab believes its UniBody technology has the potential to expand the market for targeted therapeutics, in particular for some cancer and autoimmune diseases. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
